JSW Steel achieved its highest-ever consolidated crude steel production in Q4 FY25, reaching 7.63 million tonnes (MT). This marks a 9% increase compared to Q3 FY25 and a 12% rise year-on-year (YoY).

Strong Growth in Indian Operations

The company’s Indian operations also recorded their highest-ever quarterly crude steel production at 7.40 MT, reflecting a 9% growth quarter-on-quarter (QoQ) and a 13% increase YoY. The capacity utilisation, excluding trial runs, stood at 93% for the quarter.

Read More Hexaware Tech Shares in Focus; Declare ₹5.75 Dividend for FY25, Record Date April 15. 

Production Breakdown (in million tonnes – MT)

(Includes trial run production of 0.21 MT in Q4 FY25 vs. 0.12 MT in Q3 FY25.)

Expansion at Vijayanagar Steel Plant

JSW Steel is making significant progress in expanding its 5 MTPA integrated steel project at Vijayanagar through its subsidiary, JSW Vijayanagar Metallics Ltd. (JVML).

• The 4.5 MTPA Blast Furnace, Raw Material Handling System, and Sinter Plant were commissioned in Q2 FY25.

• One out of two Converters and Casters at the Steel Melt Shop was commissioned in Q3 FY25.

• Once fully ramped up, this project will increase Vijayanagar’s crude steel capacity to 17.5 MTPA, boosting JSW Steel’s total Indian operations crude steel capacity to 34.2 MTPA.

Full-Year Production Performance (FY25)

JSW Steel’s total steel production for FY25 showed steady growth compared to the previous year.

Annual Production Breakdown (in MT)

(Includes trial run production of 0.33 MT in FY25.)

About JSW Steel

JSW Steel is the flagship business of the US$ 24 billion JSW Group, a diversified conglomerate with interests in energy, infrastructure, cement, paints, real estate, e-platforms, mobility, defence, sports, and venture capital. The company has expanded from a single manufacturing unit to become India’s leading integrated steel producer, with a consolidated crude steel capacity of 35.7 MTPA, including 1.5 MTPA in the US.

As of April 7, 2025, at 2:29 PM IST, JSW Steel share price traded at ₹925.05, down 8.02% (-₹80.70). The stock opened at ₹906, hit a high of ₹959, and a low of ₹905.20. It has a market cap of ₹2.26 lakh crore, a P/E ratio of 68.56, and a dividend yield of 0.79%. The 52-week high and low stand at ₹1,074.90 and ₹823.80, respectively.

Conclusion

JSW Steel’s record-breaking Q4 FY25 production highlights its strong growth trajectory. With capacity expansion at Vijayanagar and an aim to reach 43.5 MTPA in the next three years, the company is set to strengthen its position as a global steel leader.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

On April 7, 2025, the Nifty 50 experienced a sharp decline, closing at 21,847.00 after losing 1,057.45 points, or 4.62%. The index fluctuated throughout the day, hitting an intraday high of 22,300 before dipping to a low of 21,700.

The Nifty 50 is a broad stock market index that tracks the performance of the top 50 companies listed on the NSE. It represents crucial sectors of the Indian economy and serves as a benchmark for market performance.

Sectoral Composition of Nifty 50

The Nifty 50 represents a diverse mix of industries, with Financial Services holding the largest share at 37.30%, followed by Information Technology (11.91%) and Oil, Gas & Consumable Fuels (9.87%). Other key sectors include Automobiles (6.93%), FMCG (6.84%), and Telecommunications (4.37%), while Construction, Healthcare, and Metals each contribute around 3-4%. Smaller allocations go to Power, Consumer Services, and Capital Goods, reflecting a well-balanced sectoral representation.

Read More Nifty Smallcap 100 Falls Over 5.7% With All Stocks in the Red on Apr 7. 

Top Companies by Index Weightage

HDFC Bank leads the Nifty 50 with a 13.07% weight, followed by ICICI Bank (8.95%) and Reliance Industries (8.12%). Infosys (5.31%) and Bharti Airtel (4.37%) also hold significant shares. Other major contributors include Larsen & Toubro (3.85%), ITC (3.59%), TCS (3.46%), Kotak Mahindra Bank (3.00%), and Axis Bank (2.96%), reflecting the dominance of banking, IT, and industrial sectors in the index.

Market Trends

On April 7, 2025, Nifty 50 stocks saw significant declines, with Trent Ltd. leading the fall at -15.03%, followed by Bajaj Auto (-5.60%) and UltraTech Cement (-3.56%). Bajaj Finance (-3.85%) and Maruti Suzuki (-2.46%) also recorded losses, reflecting a broad market downturn.

Conclusion

The sharp decline in the Nifty 50 on April 7, 2025, highlights the market’s volatility amid tariff-related concerns. With all sectors experiencing pressure and key stocks like Trent and Bajaj Auto leading the losses, investors remain cautious. Moving forward, market participants will closely watch policy developments and global cues to assess potential recovery trends.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

GMR Airports share price rose 2.79% to ₹83 per share on the NSE on Monday, April 7, 2025, despite a weak market. The rise in stock price came after the company announced that its step-down subsidiary, GMR Airport Developers (GADL), had acquired GADL LLC.

Details of the Acquisition

GMR Airports stated in an exchange filing that GMR Airport Developers Limited (GADL) has set up and acquired GADL LLC, a wholly owned subsidiary in Riyadh, Saudi Arabia. The new company has been formed with a capital of 5,00,000 Saudi riyals (₹1.14 crore).

GADL LLC will provide business and management consultancy services in Saudi Arabia. The company is yet to begin operations, but this acquisition will help GADL expand in airport-related businesses.

Read More Brightcom Group Financial Results Soon; Investors Await Q4 and FY25 Performance. 

About GMR Airports Ltd

Formerly called GMR Airports Infrastructure, GMR Airports Limited (GAL) is a global airport operator. It manages Delhi, Hyderabad, Goa, and Medan airports, handling over 120 million passengers in FY 2024. The company also operates in the Philippines and Indonesia, managing Mactan Cebu International Airport and Kualanamu International Airport.

GMR Airports has a market capitalisation of ₹85,094.79 crore on the NSE.

Stock Performance

• 52-week high: ₹103.75 (July 31, 2024)
• 52-week low: ₹67.75 (February 28, 2024)
• Year-to-date gain: Nearly 4%

At 12:25 PM, GMR Airports’ stock was trading at ₹81.21, up 0.59% from the previous close of ₹80.74, while the NSE Nifty50 was down 4.62%.

Conclusion

Despite a weak market, GMR Airports’ stock gained on expansion news. The acquisition strengthens its global presence, supporting long-term growth in airport services.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

The Adani Group has purchased a valuable 1.1-acre plot in the upscale Carmichael Road area of South Mumbai for over ₹170 crore. The deal, completed through its subsidiary Mah-Hill Properties on March 27, 2025, also included a stamp duty payment of ₹10.46 crore, according to property records accessed by CRE Matrix.

Property Details and Historical Significance

The acquired land, one of the few remaining freehold plots in the Malabar Hill area, currently houses a 2,760 sq ft residential cottage. The property belonged to Behram Nowrosji Gamadia, whose family had owned it since the early 20th century. Originally designated as a children’s park under the 1991 Development Plan, the land’s classification was later changed by the Brihanmumbai Municipal Corporation (BMC) under Development Plan 2034, making it available for residential use.

Strategic Location and Investment Potential

Carmichael Road is known for its luxurious residences and proximity to key business districts, making it a sought-after address for high-end real estate investments. The exact purpose of Adani Group’s acquisition is yet to be revealed, but given the exclusivity of the location, the plot holds significant development potential.

Read More Tata Motors Share Price in Focus as Shareholders to Vote on Demerger Plan on May 6. 

Luxury Real Estate Transactions in the Area

South Mumbai’s luxury real estate market has seen several high-value transactions in recent years:

• October 2024: KKR India CEO Gaurav Trehan purchased a sea-view luxury apartment in the Morena House project on Carmichael Road for ₹88 crore. The 5,381 sq ft apartment was priced at ₹1.63 lakh per sq ft, making it one of the most expensive property deals in the country.

• June 2024: Nadir Godrej of Godrej Industries bought 3 luxury apartments in Ruparel House, Malabar Hill, for ₹180 crore.

• April 2024: Macrotech Developers (Lodha Group) sold 2 luxury apartments in Lodha Malabar on Walkeshwar Road, Malabar Hill, to Anil Gupta, chairman and MD of Wellknown Polyesters Ltd, for ₹270 crore.

Conclusion

The Adani Group’s latest acquisition adds to the growing demand for prime real estate in South Mumbai. With property values in the area consistently rising, this purchase further highlights Carmichael Road’s appeal as one of India’s most prestigious residential locations.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Oil & Gas stocks are in focus on Monday as Brent crude oil prices hover near $60 per barrel, while US WTI crude has fallen below this level. This decline in crude prices is expected to impact Indian companies involved in refining and petroleum product manufacturing.

Why Are Crude Prices Falling?

Crude oil prices have dropped due to concerns over global trade tensions. The tariffs imposed by US President Donald Trump on trade partners could reduce oil demand, potentially leading to a prolonged price decline. The ongoing trade war may push economies toward a slowdown, increasing fears of a recession.

Kristalina Georgieva, Chief of the  IMF (International Monetary Fund), highlighted that these tariffs pose a risk to global economic growth. She urged the US and its trade partners to find a resolution to ease uncertainty.

Impact on Indian Oil & Gas Companies

Indian oil & gas companies, including Reliance Industries, ONGC, Oil India, Indian Oil Corporation, and Bharat Petroleum, are expected to remain in focus today due to crude price movements.

On Friday, shares of major oil & gas firms saw significant losses:

• Reliance Industries share price fell 3.5% 
• ONGC share price dropped over 7% 
• Oil India share price declined 6.8% 
• Bharat Petroleum share price lost 2.3% 

The Nifty Oil & Gas index declined 3.78% in the last session, losing nearly 4% in a week. However, the index has gained 3.5% over the last month but has dropped 5.5% in the past three months.

Read More Mazagon Dock Shares Slide 13%; Government Ups Stake Sale via Oversubscription Option. 

OPEC+ Supply Increase Adds to Pressure

Adding to crude’s weakness, OPEC+ unexpectedly decided to increase oil production by 411,000 barrels per day from May, much higher than the previously planned 135,000 barrels. This rise in supply, along with reduced global demand due to trade tensions, is keeping crude oil prices under pressure.

Conclusion

With crude oil prices under pressure from rising supply and weak demand, oil & gas stocks may remain volatile. Investors will closely watch further developments in global trade policies and OPEC+ decisions.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Dr Reddy share price plunged 7.55% on April 7, hitting an intraday low of ₹1,025.90. The decline followed a show cause notice from the Income Tax (I-T) department regarding a tax reassessment.

Tax Notice Details

The I-T department issued a notice of ₹2,395.81 crore under Section 148A of the Income Tax Act. The notice, received on April 4, questions the company’s tax returns for the financial year 2019-20. The issue relates to the merger of Dr Reddy’s Holding Limited (DRHL) into Dr Reddy’s Laboratories Limited (DRL), which was approved by the National Company Law Tribunal (NCLT) on April 5, 2022.

Dr Reddy maintains that there is no tax evasion and is reviewing the notice before responding appropriately. The company also stated that this development will not significantly impact its financials or operations.

About Dr. Reddy’s

Founded in 1984 by Dr. Kallam Anji Reddy, Dr. Reddy’s is a Hyderabad-based pharmaceutical company. It manufactures and markets prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients (APIs). The company operates in multiple markets, including the US, Europe, Latin America, and Asia.

Dr Reddy specialises in generics, branded generics, biosimilars, and innovative formulations across key therapeutic areas such as gastroenterology, cardiology, oncology, pain management, and dermatology.

Read More Metropolis Healthcare to Acquire Dehradun’s DAPIC for ₹35 Crore to Expand North India Presence. 

Market Capitalization & Trading Status

Dr Reddy’s has a market capitalisation of ₹91,093 crore and is part of the BSE 100 index. As of 11:13 AM, the stock was trading 1.63% lower at ₹1,091.70, while the BSE Sensex had dropped 3.74% to 72,544.62.

Conclusion

Despite the sharp decline, Dr Reddy maintains that the tax notice will not impact its business. Investors will watch for further developments as the company responds.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Tata Consultancy Services (TCS) is set to announce its Q4FY25 results and full-year financial performance on April 10, 2025. Investors are eager to know whether the company will declare a final dividend, as hinted in its regulatory filing. Here are 5 key aspects to watch ahead of the announcement.

Will TCS Declare a Final Dividend?

TCS has kept the possibility of a final dividend open. The company’s Board of Directors may propose the dividend during its meeting on April 10, pending approval at the 30th Annual General Meeting (AGM).

Read more about Sensex Crashes 3,900+ Points as RIL, TCS Hit 52-Week Lows Amid Global Sell-Off.

Board Meeting and Result Announcement Schedule

TCS has notified stock exchanges that the Board will meet on April 10 to approve its Q4FY25 and full-year financial results. The announcements will follow this schedule:

• Post-market hours – Financial results will be published. 
• 5:30 PM – A press conference will provide further details. 
• 7:00 PM – An investor and analyst call will discuss the company’s performance and outlook. 

TCS Dividend History

In FY25, TCS has already distributed:

• ₹66 per share as a special dividend. 
• ₹10 per share as an interim dividend (announced in January). 

In FY24, the company rewarded shareholders with:

• ₹18 per share (January). 
• ₹28 per share (May). 
• ₹10 per share (July). 
• ₹10 per share (October). 

TCS Q3FY25 Performance Snapshot

Ahead of the Q4 results, TCS reported the following numbers for Q3FY25:

• Revenue: ₹63,973 crore, up 5.6% YoY. 
• Net Profit: ₹12,380 crore, up 12% YoY. 
• Operating Margin: 24.5%, with a 40 basis point sequential improvement. 
• Total Contract Value (TCV): $10.2 billion, with a 1.4 book-to-bill ratio. 

TCS Stock Performance Before Q4 Results

TCS shares have been under pressure ahead of its earnings release:

• Last 5 trading sessions: Down 7%. 
• 1-month performance: Down 8%. 
• 6-month performance: Down 23%. 
• 1-year performance: Down 17%. 
• Year-to-date (YTD) 2025: Down 20%. 

The stock’s 52-week high is ₹4,592.25, while the 52-week low is ₹3,295.50.

Conclusion

As TCS gears up for its Q4FY25 results, investors will be watching closely for a potential final dividend announcement. With its strong dividend history and steady growth, the upcoming board meeting will be crucial for shareholders.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Sun Pharmaceutical Industries Limited (Sun Pharma) has introduced FEXUCLUE® (Fexuprazan) 40 mg tablets in India. This new drug, a potassium-competitive acid blocker (P-CAB), is designed to treat Erosive Esophagitis in adults. FEXUCLUE® offers fast action, stable gastric acid suppression, and can be taken with or without food.

Key Benefits of FEXUCLUE®

• Fast Onset & Long-Lasting Effect: Fexuprazan works quickly and has the longest half-life (9 hours) among P-CABs, ensuring prolonged acid suppression and better night-time symptom relief.
• Clinically Proven: In a Phase 3 clinical trial in India, the drug helped over 95% of patients heal from Erosive Esophagitis within 8 weeks. It was also well tolerated among Indian patients.

Agreement with Daewoong Pharmaceutical

Sun Pharma has partnered with Daewoong Pharmaceutical Co Ltd, a South Korean company, to manufacture and sell FEXUCLUE® in India. Under this agreement, Daewoong will receive upfront and milestone payments, including royalties.

Kirti Ganorkar, CEO of Sun Pharma’s India Business, highlighted that Erosive Esophagitis significantly affects patients’ quality of life and that FEXUCLUE® is a best-in-class treatment that addresses an unmet need in managing this condition.

Understanding Erosive Esophagitis

Erosive Esophagitis occurs when the esophagus lining becomes inflamed and damaged due to prolonged exposure to stomach acid. It is considered a form of gastroesophageal reflux disease (GERD) and is linked to heartburn and regurgitation.

• Prevalence in India: GERD affects 7.6% to 30% of the population, and 9% of GERD patients develop Erosive Esophagitis.
• Current Treatment Challenges: Despite various medical, surgical, and endoscopic treatments, many patients still struggle with symptom relief and quality of life issues.

About Sun Pharma

Sun Pharma is India’s largest pharmaceutical company and a global leader in specialty generics. It operates in over 100 countries and has a strong presence in dermatology, ophthalmology, and oncology-related treatments.

As of April 7, 2025, at 10:16 AM IST, Sun Pharmaceutical Industries share price is trading at ₹1,651.75, down ₹57.60 (3.37%) for the day. The stock opened at ₹1,620.10, reached a high of ₹1,685.35, and touched a low of ₹1,620.10. Sun Pharma has a market capitalisation of ₹3.96 lakh crore, a P/E ratio of 34.61, and a dividend yield of 0.94%. The stock’s 52-week high stands at ₹1,960.35, while its 52-week low is ₹1,377.20.

Read more about Siemens Share Price Drops 50% Post-Demerger with Siemens Energy India.

About Daewoong Pharmaceutical

Daewoong Pharmaceutical is a leading South Korean healthcare company known for its research in new drug development. It launched Fexuprazan for GERD in 2022 and introduced a diabetes drug, Enavogliflozin, in 2023.

Conclusion

With FEXUCLUE®, Sun Pharma strengthens its commitment to innovative treatments in gastroenterology. This launch offers new hope for patients struggling with Erosive Esophagitis.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.